ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2009 Annual Meeting

Click here to go to the previous page

Management of Primary, Refractory and Recurrent Diffuse Large B Cell and Other Aggressive Lymphomas

Track : Educational Session

Program Code: EDU413

Date: Wednesday, November 4, 2009

Time: 1:45 PM to 3:15 PM EST

Duration: 90 Minutes

Location: W178

SPEAKER(S):

Richard Tsang, Professor, Princess Margaret Hospital

David Hodgson, Radiation Oncologist, Princess Margaret Hospital

David C. Hodgson, MD, MPH, is an Associate Professor and clinician scientist in the Department of Radiation Oncology, and Department of Health Policy, Management and Evaluation, University of Toronto. He is a staff radiation oncologist at the Princess Margaret Hospital and an Adjunct Scientist at ICES, and holds a Cancer Care Ontario Research Chair in Health Services Research. He received his medical degree and radiation oncology training at the University of Toronto and subsequently obtained a Masters degree in Public Health from Harvard University. He is a member of the Hodgkin Lymphoma Steering Committee, and the Cardiac Late Effects Task Force of the Childrens Oncology Group, and also the Haematology Disease Site Group of Cancer Care Ontario.David C. Hodgson, MD, MPH, is an Associate Professor and clinician scientist in the Department of Radiation Oncology, and Department of Health Policy, Management and Evaluation, University of Toronto. He is a staff radiation oncologist at the Princess Margaret Hospital and an Adjunct Scientist at ICES, and holds a Cancer Care Ontario Research Chair in Health Services Research. He received his medical degree and radiation oncology training at the University of Toronto and subsequently obtained a Masters degree in Public Health from Harvard University. He is a member of the Cardiac Late Effects Task Force of the Childrens Oncology Group, the Haematology Disease Site Group of Cancer Care Ontario. His research activities include the utilization of population-based health administrative data to evaluate the treatment and outcome of cancer patients, particularly late effects.

Andrea Ng, Brigham and Women's Hospital

Selected Presentations 2000 Rhode Island Cancer Council Forum on �Successful Survivorship After Cancer�. Invited Speaker on �Continuing Healthcare After Successful Cancer Treatment�, Warwick, RI 2002 International Symposium on Advanced Tumor Prevention & Therapy; Invited Speaker on �Hodgkin�s Disease: Current Treatment and Late Effects�, Jinan, Shandong, China 2003 Recruiting high risk women into randomised intervention trials in the US�, Invited Speaker, Christie Hospital, Manchester UK 2003 Improving Survival and Quality of Life of Long-Term Survivors of Hodgkin�s Disease�. Invited Speaker, The Rockefellar Foundation Bellagio Study and Conference Center, Lake Como, Italy 2004 Hodgkin Lymphoma Late Effect Study Group. Invited Speaker on �A Prospective Cardiac Screening Study in Survivors of Hodgkin�s Disease�, The 6th International Symposium on Hodgkin's Disease, Cologne, Germany 2004 NCI Second Cancers workshop �Cancer Survivorship: Genetic Susceptibility and Second Primary Cancers�. Invited Speaker on �Current Work in Second Primary Cancers and Other Late Effects of Hodgkin�s Disease�, Bethesda, MD 2006 Visiting Professor at Cleveland Clinic, Department of Radiation Oncology, Cleveland, OH 2006 Cancer Survivor Research and Education, CURED I Meeting. Invited Speaker on �Breast MRI Screening for Female Survivors of Hodgkin�s Disease�, Rochester, NY 2006 ASTRO Panel on �Cancer Survivorship�, Co-Chair, Philadelphia, PA 2007 ASCO Educational Session on �Survivors of Hodgkin�s Disease: the Evolving Picture of Cancer Care�. Invited Speaker, Chicago, IL 2007 Hodgkin Lymphoma Cancer Survivorship Workshop. Invited Speaker on �Breast MRI Screening for Survivors of Hodgkin�s Disease�, The 7th International Symposium on Hodgkin's Disease, Cologne, Germany Selected Publications: Ng AK, Bernardo MP, Weller E, et al. Second Malignancy After Hodgkin�s Disease: Long-Term Risk and Risk Factors. Blood 100:1989-1996, 2002 Ng AK and Mauch PM. Second Malignancy After Hodgkin�s Disease. The American Journal of Oncology Review 2003; 2:190-2003 Ng AK, Mauch PM. Late Complications of Therapy of Hodgkin's Disease-Prevention and Management. Current Hematology Reports 2004; 3(1):27-33 Mauch P, Ng A, Aleman B, et al. �Report from the Rockefellar Foundation Sponsored Workshop on Reducing Mortality and Improving Quality of Life in Long-Term Survivors of Hodgkin�s Disease, Held July 9-16, 2003, Bellagio, Italy� Eur J Haematol 75 Suppl 66: p. 68, 2005 Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH. Cancer Survivorship - Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations. JNCI 98:15-25. 2006 Ng AK, Mauch PM. The impact of treatment on the risk of second malignancy after Hodgkin's disease. Ann Oncol 17: 1727-1729, 2006 Friedberg JW and Ng, AK. �Epidemiology of Second Malignancies Following Lymphoma Therapy and Screening Recommendations� In: Sekeres MA, eds �Clinical Malignant Hematology�; 2007, p 815-822 Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects. J Clin Oncol 25:3991-4008, 2007 Ng AK, Travis LB. Second Malignant Neoplasms: An Overview. Hematology/Oncology Clinics of North America 22:271-289, 2008

Audio Synchronized to PowerPoint

(Code: EDU413)